Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)

Historic Asset Writedowns and Impairment for Avalo Therapeutics (AVTX) over the last 1 years, with Q4 2018 value amounting to $38438.0.

  • Avalo Therapeutics' Asset Writedowns and Impairment changed N/A to $38438.0 in Q4 2018 from the same period last year, while for Sep 2020 it was $38438.0, marking a year-over-year decrease of 9797.69%. This contributed to the annual value of $1.4 million for FY2019, which is 2373.05% down from last year.
  • Latest data reveals that Avalo Therapeutics reported Asset Writedowns and Impairment of $38438.0 as of Q4 2018.
  • Avalo Therapeutics' 5-year Asset Writedowns and Impairment high stood at $1.7 million for Q2 2018, and its period low was $38438.0 during Q4 2018.